ChemPartner now offers innovation-focused CRO service for collaboration in small molecule drug discovery with a unique US/China blended team research model. An accomplished team of pharma industry-experienced scientists based in South San Francisco propose and implement strategies in early stage drug discovery research, managing laboratory execution mostly in China. Our experts in medicinal chemistry provide solutions for hit identification, lead optimization, preclinical candidate selection and IP creation. With expertise across a range of target classes we have the capability to explore small-molecule, peptide and biologic modalities for most therapeutic areas. Research project leadership at the South San Francisco site is supported by extensive cross-functional capability from our chemistry, biology, DMPK and CMC groups in China. The blended team research model is a value-added, highly responsive and customizable approach to progressing drug discovery research programs from target validation to preclinical development candidate nomination.
Bespoke Models for Collaboration
Tailored to suit the needs of the client, our medicinal chemists can provide services ranging from program management, compound design, chemical synthesis development, assay development and screening paradigms and DMPK profiling. Our expertise is offered either on an as-needed basis as consultants or as part of an FTE arrangement, whichever suits the project needs and budget. A US-based team leader affords advantages of responsiveness and convenience in communication between the client and ChemPartner.
The blended team model is customizable to each client’s requirements and is appropriate for most entities engaged in drug discovery research. We serve traditional large pharmaceutical companies that wish to easily increase their discovery research capacity, virtual start-ups that need a ready-made research capability, academic institutions seeking to implement drug discovery efforts born in their research groups and any organization that requires an experienced, fully-enabled drug discovery research capability to realize their objectives for new therapeutics.